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Abstract 
 Introduction: Hyperlipidemia is a modifiable risk factor of an 
important killer disease “cardiovascular diseases”, research work exploring 
anti- hyperlipidemic activity of local plant is timely gesture. Aim: To 
investigate anti-hyperlipidemic ability of aqueous fruit pulp extract of 
Adensonia digitata in experimental rats. Methodology: Hyperlipidemia was 
induced in rats via feeding on high lipid diet (HLD) for 3 weeks. A total of 
42 rats used, were divided into seven groups (GI - GVII) of six rats each. GI 
served as normal control, GII were normal rats administered with only the 
extract and GIII serves as hyperlipidemic control group. While GIV, GV and 
GVI were hyperlipidemic group administered with the extract at a dose of 
1.25g/kg, 2.5g/kg and 3.75g/kg body weight respectively and GVII were 
hyperlipidemic given standard hyperlipidemic drug (atorvastatin), the 
hyperlipidemic rats were on high cholesterol diet throughout the study 
period.  At the end of the first week of extract administration, three animals 
from each group were randomly selected and sacrificed. At the end of the 
second week, the remaining three animals from each group were also 
sacrificed and serum was collected for analysis of serum lipid profile (Total 
Cholesterol, LDL-Cholesterol, HDL-Cholesterol and Triglyceride). Results: 
Significant decrease (p< 0.05) in the serum TC, TG, LDL-C, and a 
significant increase in the HDL-C levels was observed with 1.25g/kg, 
2.50g/kg and 3.75g/kg in group IV, V and VI, and group VII treated with 
Atorvastatin when to compared with the hyperlipidemic control both in the 
first and second week of treatment. Conclusion: The study demonstrated 
that A. digitata aqueous fruit pulp extract possesses anti-hyperlipidemic 
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property. The effects may be associated with the phytochemical content of 
the plant pulp. Further studies on the plant may focus on identification, 
isolation of active component(s) aimed at formulating anti-hyperlipidemic 
drugs from natural source. 
 
Keyword: Adensonia digitata, High fat diet, Hyperlipidemia, lipid profile.    
 
Introduction 
 Hyperlipidaemia or hyperlipoproteinemia involves abnormally 
elevated levels of any or all lipids fraction in the blood. It is the most 
common form of dyslipidaemias (Mathers and Loncar, 2006). The 
abnormalities are common in the general population, and are regarded as 
modifiable risk factors for cardiovascular diseases (CVDs) due to their 
influence on atherosclerosis (Torelli and Ryan, 2005). Atherosclerosis is a 
syndrome affecting arterial blood vessels due to a chronic inflammatory 
response of white blood cells in the walls of arteries. This is promoted by 
low-density lipoproteins, cholesterol and triglycerides without adequate 
removal of fats and cholesterol from the macrophages by functional high-
density lipoproteins (HDL). It is commonly referred to as a hardening or 
furring of the arteries, caused by the formation of multiple atheromatous 
plaques within the arteries (Ross et al., 1999). In addition, some forms may 
predispose to acute pancreatitis. Most cardiovascular diseases can be 
prevented by addressing risk factors such as tobacco use, alcohol intake, 
unhealthy diet and obesity, physical inactivity, high blood pressure, diabetes 
and raised blood lipids (Thompson, 2004). 
 Adansonia digitata, commonly known as the baobab, belongs to the 
family Malvaceae and is the most widespread of the Adansonia species in the 
African continent, found mostly in hot, dry savannah of sub-Saharan Africa.  
It is called “kukah” by many ethnic groups in Nigeria (Aliyu. 2006). The 
baobab has been used extensively since ancient times in traditional medicine. 
Baobab bark is mainly used for its medicinal properties and for its fibres 
(Sidibe and William, 2002). The alkaloid ‘adansonin’ in the bark is thought 
to be the active principle for treatment of malaria and other fevers, as a 
substitute for quinine. Several plant parts have interesting anti-oxidant, anti-
micobial and anti-inflammatory properties. The pulp is commonly used 
among Hausa – Fulani in preparing plant made local yoghurt or as additive 
to traditional yoghurt offered for sale by Fulani women. The hypothesis is 
that feeding on high lipid diet induces hyperlipidemia and or dyslipidemia, 
and simultaneous feeding of the hyperlipidemic rats with the high fat diet 
and aqueous extract of A. digitata may abate, revert or suppress the 
hyperlipidemic condition.  
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Material and methods 
Material 
Experimental Animals 
 Male and female albino rats weighing between 80g to 120g were 
purchased from animal house of Biological Science Department, Bayero 
University, Kano. The animals were housed in well-ventilated cages in the 
animal house of Biological Science Department of Bayero University Kano.  
The rats had access to food and water. Principle of laboratory animal care 
(NIH Publication No. 85-23) (NIH, 1996) and ethical guidelines for 
investigation of experimental pain in conscious animals (Zimmermann, 
1983) were observed during experimentation.  
 
Plant Material 
 The fruits of Adansonia digitata was collected in Gosa community in 
Abuja Municipal Area Council and Gwargwada community in Kuje Area 
Council of the Federal Capital Territory (Abuja). The plant was identified 
and authenticated at the herbarium of the Department of Plant Biology, 
Bayero University Kano by a plant taxonomist, Bala’uddeen Said Adam on 
31th October, 2014 with Accession Number BUK HAN0036. 
 
Methods 
Preparation of Aqueous Fruit Pulp Extract f A. digitata (Afpead) 
 The collected fruit pulp was finely ground into powder form by using 
pestle and mortar. The seeds were separated from the pulp using a mesh. The 
fineness of the powdered pulp was achieved by sieving through a clean white 
muslin cloth allowing the fibres to be completely removed. The powder was 
stored in a clean air-tight plastic container at room temperature until use. 
Accurately 20g of the powder was weighed into 100ml of distilled water to 
prepare a concentration of 200mg/ml of Aqueous Fruit Pulp Extract of 
Adensonia digitata (AFPEAD) for administration to experimental animals in 
24 hours.  
 
Administration of AFPEAD to Animals 
 The volume of the extract to administer to the experimental rats was 
determined based on the weight of the animals using the following 
relationship. 
)/(
)()/()(
mlmgextractofionConcentrat
kgratofweightkgmgDosemlVolume ×=
 
 
 
 
European Scientific Journal April 2016 edition vol.12, No.12  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
 
301 
Induction of Hyperlipidemia in Rats 
 The high fat diet was formulated using the method of Vesselinvitch et 
al (1980) which is as follows: Pure cholesterol and palm oil were thoroughly 
mixed with the grower mash feed on a percentage ratio of 2:20:78 to 
formulate high lipid diet (HLD). The HLD was given to the animals for a 
period of three weeks to induce hyperlipidemic condition in the rats. The 
hyperlipidemic rats were maintained on the HLD throughout the study 
period.   
 
Experimental protocol  
 The research involves the investigation of the effect of oral 
administration of aqueous extract of A. digitata on blood lipid profile in 
hyperlipidemic rats. A total of forty-two (42) rats were used, and grouped 
into seven (7) of six (6) rats each as follows: 
 Group I:   normal control, not administered with AFPEAD 
 Group II:  non- hyperlipidemic, administered with 2.5g/Kg of 
AFPEAD daily for two weeks 
 Group III:  hyperlipidemic control, not treated with AFPEAD daily 
for two weeks  
 Group IV:  hyperlipidemic rats treated with 1.25g/Kg of AFPEAD 
daily for two weeks  
 Group V:   hyperlipidemic rats treated with 2.5g/Kg of AFPEAD 
daily for two weeks  
 Group VI:  hyperlipidemic rats treated with 3.75g/Kg of AFPEAD 
daily for two weeks  
 Group VII: hyperlipidemic rats treated conventional anti 
hyperlipidemic drug (atorvastatin 10mg /Kg) daily for two weeks. 
 GIII – GVII were fed on high cholesterol diet throughout the 
experimentation. At the end of the first week, three animals from each group 
were selected randomly and sacrificed the remaining three animals continue 
to receive the treatment for another week and were sacrificed at the end of 
the second week.  
 
Estimation of Parameters 
 Serum HDL and LDL-Cholesterol were assayed by the method of 
Friedward et al (1972), Triglycerides by the method of Trinder (1969) and 
Total Cholesterol by the method of Trinder (1969). 
 Artherogenic index was calculated using the formula as describe by 
Shinde et al (2013). 
𝐴𝑡ℎ𝑒𝑟𝑜𝑔𝑒𝑛𝑖𝑐 𝐼𝑛𝑑𝑒𝑥 (𝐴𝐼) = 𝑇𝑜𝑡𝑎𝑙 𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 − 𝐻𝐷𝐿 𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙
𝐻𝐷𝐿 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙  
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Percentage increases or decreases were calculated using the relation: % =  Xs –  CvCv  × 100 
Where;  
 Xs = Sample value, Cv = Reference Value (Normal control or high 
lipid diet (HLD) feed group). 
 
Statistical Analysis 
 Results were expressed as mean ± standard deviation and analysed 
using ANOVA followed by students t test in which P<0.001 considered 
significant. 
 
Results and discussions 
 Table1 presents the body weight in gram of dietary induced 
hyperlipidemic groups of rats treated with various concentrations of 
AFPEAD and a pharmaceutical anti – hyperlipidemic drug (atrivin) for seven 
(7) and fourteen (14) days. At end of  three weeks inducement period (before 
treatment) there was no significant difference (P>0.001) except between GI 
and GII compared to GIII, GIV, GV, GVI and GVII, which may be 
attributed to the inducement of hyperlipidemia, hence becomes obesity 
prone. The trend was maintained in one and two week (s) of treatment of the 
hyperlipidemic condition with   AFPEAD except for GIII that show a 
significantly higher (P<0.001) body weight compared to the remaining 
groups in both weeks of the treatment. The observed significant body weight 
gain in GIII in one and two weeks was not observed in treated 
hyperlipidemic groups (GIV – GVII) which may be attributed to anti – 
hyperlipidemic activity of the AFPEAD in GIV, GV and GVI and artirivin 
drug in GVII.   Figure 1 depicted percentage body weight gain for group of 
experimental rats. GI and GII show similar % wt gain less than the 
hyperlipidemic groups. GIII show highest % wt gain compared to treated 
hyperlipidemic groups (GIV, GV, GVI and GVII). Table 2 and 3 presents the 
effect of HLD and AFPEAD on indices of lipid profile (TCh, HDL-Ch, TG 
and LDL-Ch) in rats, in three weeks of feeding on the HLD and after one and 
two weeks of treatment of the hyperlipidemic rats with AFPEAD 
respectively. The result shows a significant increase (P<0.001) in TCh, LDL-
Ch, TG, artherogenic index (AI) and a significant decrease in HDL-Ch in 
hyperlipidemic negative control (G III) compared to normal control (G I). A 
significant decrease (P<0.001) in TCh, LDL–Ch, TG and AI was observed in 
treated hyperlipidemic rats compared to GIII. Figure 2 and 3 present the 
percentage increase and decrease in lipid profile indices and artherogenic 
index; for HLD feed with neither extract nor drug (GIII) with respect to 
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normal control (GI) and for test groups (GIV, GV, GVI and GVII)  with 
respect to the negative control (GIII).      
Table 1: Body weight of rats feed with high lipid diet (HLD) for three weeks and treated 
with extract of Adensonia digitata  and atrovastatin drug for 7 and 14 days. 
Group 
Duration 
GI 
contro
l 
GII 
2.5g/K
g 
AFPE
AD 
GIII 
Hyperli
pid. 
Control 
GIV 
1.25g/
Kg 
AFPE
AD 
GV 
2.5g/K
g 
AFPE
AD 
GVI 
3.75g/
Kg 
AFPE
AD 
GVII 
10mg/
Kg 
atv 
3week of HLD feed 
95.00a,
b,c 
± 
1.67e 
96.17 
a,b,c 
± 
1.56e, 
107.33 
a,b,c 
± 
1.67f, 
107.00 
a,b,c 
± 
1.33 f 
106.83 
a,b,c 
± 
1.89 f 
107.50 
a,b,c 
± 
2.33 f 
106.33 
a,b,c 
± 
2.33 f 
One  Week of extract 
administration 
119.67 
a, c 
± 
3.00e 
121.67 
a,c 
± 
2.67e 
154.00 
a,c 
± 
2.67 
139.17 
a,c 
± 
2.22u 
139.17 
a,c 
± 
2.50u 
141.17 
a,c 
± 
1.89u 
138.67 
a,c 
± 
1.00u 
Two weeks of extract 
administration 
148.00 
b, c 
± 
1.33 
153.00 
b,c 
± 
2.00 
201.33 
b,c 
± 
2.44 
189.33 
b,c 
± 
0.89w 
190.33 
b,c 
± 
0.44w 
190.00 
b,c 
± 
0.67w 
186.00 
b,c 
± 
1.33 
Values in same column bearing similar super script differ significantly at P <0.001, while 
value across the rows bearing same subscript are not significantly different (P> 0.001). 
Figure 1: percentage body weight gain for hyperlipidemic of rats treated for two weeks 
 
Table 2: Serum lipid profile (mMol/L) and Artherogenic index (AI) of hyperlipidemic rats 
administered with AFPEAD for seven (7) days. 
Group    TChol  HDL-Chol                       TG                 LDL-Chol                     AI 
GI 4.19±0.02a,  2.29±0.07a          1.10±0.02a  1.40±0.01a   0.83±0.03 
GII 4.13±0.04   2.09±0.16          1.33±0.08  1.76±0.01   0.98±0.01 
    GIII 5.17±0.06a,b,c,d,e 1.73±0.08a,b,c,d,e     1.75±0.05a,b,c,d 2.68±0.10a,b,c,d,e                                     1.99±0.02 
G IV 4.37±0.03b    2.37±0.02b  1.31±0.02b  1.38±0.03b  0.84±0.02 
G V 4.27±0.03c    2.04±0.04c  1.21±0.01c  1.70±0.07c   1.09±0.04 
G VI 4.25±0.01d    2.07±0.09d  1.32±0.02d  1.74±0.02d   1.05±0.04 
GVII 4.27±0.03e          2.15±0.02e  1.28±0.02e  1.46±0.03e  0.99±0.03 
 
 
 
0
10
20
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40
50
GI GII GIII GIV GV GVI GVII
 1st wk % Body Wt. gain 2nd wk % Body Wt. gain
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Results are expressed as mean ± SD, (n=3). Values in the same column 
with similar superscripts are significantly different at P<0.05. 
 
 
Figure 2: percentage increase (   ,    ) and decrease (    ,     ) in lipid profile indices and 
artherogenic index for 
hyperlipidemic rats treated for one week  (              ,                respectively compared to 
normal control and to high lipid diet 
 
Table 3: lipid profile of hyperlipidemic rats administered with AFPEAD for fourteen (14) 
days 
Groups   TC (mMol/L)     HDL-c (mMol/L)             TG (mMol/L)   LDL-c (mMol/L)     Artherogenic index 
 
G I 4.17±0.06a     1.75±0.02a  1.13±0.01a    1.80±0.04a  1.38±0.03 
G II 4.28±0.03     1.63±0.04  1.23±0.07    2.17±0.04  1.68±0.05 
   G III  7.15±0.02a,b,c,d       1.04±0.01a,b,c,d,e,                        2.23±0.06a,b,c,d,e    5.08±0.02a,b,c,d,e                       5.88±0.04 
G IV 4.28±0.03b     1.85±0.04b            1.18±0.03b    2.85±0.09b  1.31±0.04 
G V 5.07±0.06c     1.70±0.06c  1.12±0.01c    2.86±0.07c  1.98±0.07 
G VI 5.72±0.10d     1.72±0.06d  1.17±0.01d    2.64±0.07d  2.33±0.05 
GVII 4.83±0.11e     1.84±0.08e  1.27±0.03e    2.53±0.06e    1.630±0.06 
 
Results are expressed as mean±S.D (n=3). Values in the same column with same 
superscripts are significantly different at P<0.05. 
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Figure 3: percentage increase (   ,    ) and decrease (    ,     ) in lipid profile indices and 
artherogenic index for hyperlipidemic rats treated for two weeks  (              ,                
respectively compared to normal control and to high lipid diet ) 
 
Discussions     
 From table 1the significant difference (P<0.001) in body weight 
when compared GI and GII with groups (GIII - GVII) across the raw within 
three weeks on HLD shows that rats in GIII, GIV, GV,  GVI and GVII are 
prone to obesity, induces by three weeks HLD feeds. The finding is in 
accordance with that of Vesselinvitch et al (1980); suggested that a dietary 
fats induced hyperlipidemic rat is obesity prone. Figure 1 may justify the 
statement of Vesselinvitch et al (1980), in which GIII indicated highest 
percentage weight gain compared to both normal control and treated 
hyperlipidemic groups. The reduced percentage body weight gain in GIV, 
GV and GVI could be associated with administration of the Adensonia 
digitata extract. It may infer that the extract reduces the accumulation of 
lipid in the rats. The inducement of hyperlipidaemia was evident by the 
differences in serum lipid profile indices between GI and GIII, in which the 
later show significantly higher lipid profile indices compared to the former 
due to the intake HLD. This echo well with statement of Austin (2007) who 
lamented that hyperlipidemic condition is presented with elevated serum 
total cholesterol, low density lipoprotein, very low density lipoprotein (LDL) 
cholesterol, reduced high density lipoprotein (HDL) or elevated 
hypertriglyceridemia. It is well documented that dyslipidemia, particularly 
hypercholesterolemia, induces tissue damage or provokes several human 
0
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diseases (Ma et al., 2011). In a similar vein hypertriglyceridemia with 
concomitant hypercholesterolemia may be responsible for oxidative 
modification of LDL, protein glycation, glucose-autooxidation with excess 
production of free radicals and lipid peroxidation products (Yang et al., 
2008), which represent major risk factors for ischemic heart diseases 
(Vandewoude, and Vandewoude, 1987; Carr et al., 2000; Howard et al., 
2006). It may be true that reversal / reduction of dyslipidaemic condition in 
the hyperlipidemic rats models in this study prevent the provocation of the 
above mentioned diseases.      
 The significant higher body weight of GIII (Table 1) compared to the 
remaining groups in first and second weeks of the AFPEAD administration 
specifically in GIV, GV and GVI, may suggest or proved the acclaimed 
weight controlling ability of the plant among Hausa – Fulani of Northern 
Nigeria. The observed significant (P< 0.001) decrease in the serum total 
cholesterol, triglycerides, LDL-cholesterol, and a significant increase in the 
HDL-cholesterol in hyperlipidemic rats treated with 1.25g/kg, 2.50g/kg and 
3.75g/kg body weight of the extract (G IV, GV and GVI) and GVII treated 
with the drug atorvastatin (Atv) when to compared with the hyperlipidemic 
control (GIII) in both first and second week of treatment. This may suggest 
anti-serum hyperlipidemic activity of the plant which was comparable with 
the pharmaceutical agent (atorvastatin), the effect could be due to some 
phytochemical content of the plant pulp that may influences lipid metabolism 
thereby affect  the serum lipid profile indices as does by the statins. The 
decreased serum cholesterol in the groups of rats treated with extract might 
be due to increased activity of enzyme LCAT (lecithin cholesterol 
acyltransferase) involved in esterification of cholesterol in the plasma. The 
significant decrease in serum triglycerides (TG) could be due to decreased 
accumulation of lipoprotein, associated with increased activity of lipoprotein 
lipase that involved in the uptake of TG rich lipoprotein by extra hepatic 
tissue. Other possible mechanisms by which AFPEAD regulates serum lipids 
profile may includes increasing LDL receptors of the hepatocytes or 
suppressing HMG-CoA reductase and thus lower the plasma and hepatic 
cholesterol concentrations (Lee et al., 1999).  
 It is imperative to note that statins a class of drugs used to lower 
cholesterol levels by inhibiting HMG-CoA reductase (Spindler et al., 2012), 
to limit production of mevalonate (Taylor et al., 2013). This is significant 
because most circulating cholesterol comes from endogenous synthesis 
rather than the diet. When the liver can no longer produce cholesterol, levels 
of cholesterol in the blood definitely falls (Endo, 1992). A number of statins 
include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, 
rosuvastatin and simvastatin (Sweetman, 2009). It may be suggested that 
AFPEAD might be acting in the same mechanism for its hypolipedemic 
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effect. This may be due to its contents and wide varieties of phytochemicals, 
including glycosides, tannins, quinic acid and a host of others.  
 
Conclusion 
 Base on this study Adensonia digitata pulp could be used in 
controlling lipids accumulation hence body weight.    
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